FDA Panel Says Leave DXM Unscheduled For Now, Urges Congressional Action
This article was originally published in The Tan Sheet
Executive Summary
Dextromethorphan likely will escape scheduling as a controlled substance in the near term, but manufacturers and lawmakers should push efforts to curb abuse to keep the cough suppressant available OTC in the long run